PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+osteosarcoma: A children's oncology group pediatric early-phase clinical Trial Network study.

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2023
This article has no abstract
Epistemonikos ID: c9406fe9733bd39d1d6474765a8b87f9f9e04c00
First added on: Feb 19, 2025